华泰联合证券有限责任公司 一、日常关联交易基本情况 （一）日常关联交易概述 南京药石科技股份有限公司（以下简称"药石科技"或"公司"）在 2023 年上 半年采购商品、接受劳务发生的关联交易 11.8 万元，出售商品、提供劳务发生 的关联交易 717.2 万元，合计 729.0 万元，目前尚未达到董事会审议及单独披露 标准。 鉴于部分关联公司（系公司参股公司）研发进展顺利，预计下半年将继续向 公司采购商品及服务，关联交易将继续产生，公司预计公司及子公司 2023 年度 日常关联交易总金额不超过 3,650 万元。2023 年 8 月 14 日，公司第三届董事会 第二十四次会议及第三届监事会第十五次会，审议通过了《关于 2023 年度日常 关联交易额度预计的议案》，关联董事杨民民、独立董事 WEIZHENG XU 已对该 议案回避，其余独立董事对上述关联交易事项进行了事前认可，并发表了明确同 意的独立意见。根据《深圳证券交易所创业板股票上市规则》《公司章程》等相 关规定，本次日常关联交易预计总金额在董事会审批权限范围内，无需提交公司 股东大会审议。 1 关于南京药石科技股份有限公司 2023 年度日常关联交易额 ...

华泰联合证券有限责任公司 关于南京药石科技股份有限公司 2023 年上半年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：药石科技 | | --- | --- | | 保荐代表人姓名：唐澍 | 联系电话：025-83387726 | | 保荐代表人姓名：季李华 | 联系电话：025-83387680 | 根据《证券法》《深圳证券交易所上市公司自律监管指引第 13 号—保荐业务》 和《深圳证券交易所创业板股票上市规则（2023 年修订）》等有关法律、法规的 规定，华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为南京药石科技股份有限公司（以下简称"药石科技"、"公司"或"发行人"） 向特定对象发行股票、向不特定对象发行可转换公司债券的保荐机构，对药石科技 进行持续督导，并出具本持续督导跟踪报告： 二、保荐机构发现公司存在的问题及采取的措施 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1.信息披露 | 无 | 不适用 | | 2.公司内部制度的建立和执 | 无 | 不适用 | | 行 | | | | 3."三会 ...

（一）可转债发行情况 经中国证券监督管理委员会《关于同意南京药石科技股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2022]622 号）同意，公司 于 2022 年 4 月 20 日向不特定对象发行可转换公司债券 1150 万张，发行价格为 每张面值 100 元人民币，按面值发行，募集资金共计人民币 1,150,000,000.00 元。 | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2023-073 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于不向下修正药石转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 2023 年 7 月 22 日至 2023 年 8 月 11 日，南京药石科技股份有限公司（以下 简称"公司"）股票已出现在任意连续三十个交易日中至少有十五个交易日的收盘 价低于当期转股价格的 85%（即 69.22 元/股）的情形，触发"药石转债"转股价 格的向下修正条款。2023 年 8 月 ...

证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 编号：2023-02 证券代码：300725 证券简称：药石科技 经完成超过 40,000 砌块化合物的自主合成，在三元环、四元环、桥环、 螺环、五元脂肪环、六元脂肪环、芳香杂环等领域处于行业领导地位； 同时，实时跟踪全球研发热点，快速开发和供应氘代药物分子、 PROTAC、ADC 和寡核苷酸等新化学实体相关的新颖分子砌块。公司 具备完善的合成、工艺开发和生产能力，稳定的原料供应管理，可持续 供应从克级、公斤级到吨级的分子砌块产品，支持新药研发、开发至商 业化需求，为客户项目的推进提供重要保障。 Q：请问贵公司在国内和国外的业务各占比多少，在哪些国家占比最 高？ A：投资人，您好。公司来自于国外的业务占总体 60-70%左右，目前主 要集中在欧美地区。 Q： 请问公司 ADC 业务占比是多少，未来前景如何？ A：ADC 相关能力正在建设中，目前占收入的比重整体还不高。公司依 托公司分子砌块独特资源，已推出了近百条的 linker-payload 目录以及 近千条的 linker 目录，部分 linker 产品已完成交付， ...

证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 编号：2023-01 | 投资者关系活 | □特定对象调研 □分析师会议 □媒体采访 | | --- | --- | | 动类别 | √业绩说明会 □新闻发布会 □路演活动 | | | 其他（电话会议） □现场参观 □ | | 参与单位名称 | 本次业绩说明会由国盛证券、兴业证券、广发证券、开源证券联合组 | | 及人员姓名 | 织，线上投资者共 人参会。 248 | | 时间 | 年 月 日 上午 2023 4 23 | | 地点 | 采用进门财经平台以网络远程的方式进行业绩交流 | | 上市公司接待 | | | | 杨民民 董事长、总经理 朱经伟 董事、副总经理 | | | 陈志华 CDMO 副总裁 | | 人员 | 余善宝 研发事业部负责人 | | | 李进 药物化学高级总监 | | | 吴奕斐 财务总监、董事会秘书 | | | 一、管理层介绍公司战略及 年、2023 年一季度经营情况（具体见 2022 | | | 附件演示材料） | | | 公司自 2008 年开始运营以来，以药物发现阶段的分子砌块作为切 | | ...

专注化学 创新未来 药石科技2022年度 & 2023年一季度业绩交流 2023年4月23日 www.pharmablock.com product.pharmablock.com 本次业绩交流会的相关信息、材料的所有知识产权及权利均属于南京药石科技股份有限公司（"药石科技"或"公 司"）所有，任何人未经药石科技事先许可，不得对会议进行录音、录像或以任何形式对外传播会议相关材料。本 次会议并非意图提供相关事项的完整表述，有关信息请以公司在深圳证券交易所网（www.szse.cn）和公司指定媒体 刊登的2022年年度报告及2023年第一季度报告为准。 2 公司战略 § 通过化学和技术创新，提升产品和服务在质量、EHS合规、成本和速度上的竞争力 药物发现 临床前 临床I-III期 商业化 创新技术中心（TIC） (连续流技术、微填充床技术、金属催化、生物催化、设备工程) 小分子 PROTAC ADC 寡核苷酸 肽类 1. DELT/FBDD/AIDD库 2. H2L and LO to PCC服务 注册起始物料/中间体/原料药/制剂 (工艺化学、技术转移和生产、固态化学、质量分析、注册申报) 药物发现的分子砌块 ...

Financial Performance - The company's revenue for 2022 was ¥1,594,699,978.41, representing a 32.71% increase compared to ¥1,201,629,070.94 in 2021[23]. - Net profit attributable to shareholders decreased by 35.42% to ¥314,223,824.02 in 2022 from ¥486,559,403.95 in 2021[23]. - The net profit after deducting non-recurring gains and losses increased by 14.15% to ¥265,972,288.46 in 2022[23]. - The total assets at the end of 2022 were ¥4,862,189,119.46, a 38.65% increase from ¥3,506,922,491.19 at the end of 2021[23]. - The net assets attributable to shareholders increased by 9.48% to ¥2,657,635,982.95 at the end of 2022[23]. - The basic earnings per share decreased by 35.77% to ¥1.58 in 2022 from ¥2.46 in 2021[23]. - The cash flow from operating activities was ¥246,608,762.55, a 3.60% increase from ¥238,029,950.44 in 2021[23]. - The company reported a weighted average return on equity of 12.44% in 2022, down from 22.61% in 2021[23]. - The quarterly revenue for Q4 2022 was ¥409,997,868.92, showing a slight decrease from Q3 2022[26]. - In 2022, the company reported a total non-operating income of approximately $48.25 million, a significant decrease from $253.56 million in 2021[30]. Business Operations - The company operates in the global drug research and development sector, focusing on innovative chemical products and services, including drug molecular building blocks and CDMO services[3]. - The company’s main business includes the development, production, and sales of drug intermediates and active pharmaceutical ingredients[3]. - The company has a comprehensive drug discovery technology platform and offers technology transfer services based on drug molecular building blocks[3]. - The company has a focus on expanding its market presence and enhancing its research capabilities in drug development[3]. - The company has established partnerships with nearly all of the top 20 global pharmaceutical companies and hundreds of small to medium-sized biotech firms[43]. - The company has a project pipeline with 1,750 projects in preclinical to Phase II and 60 projects in Phase III to commercialization, indicating sustainable growth[64]. Research and Development - The company has developed a diverse library of molecular building blocks, enabling rapid design and synthesis for drug discovery, significantly reducing R&D costs and timelines[40]. - The company’s R&D expenses amounted to 168 million yuan, an increase of 54 million yuan or 47.62% year-on-year, with an R&D expense ratio of 10.56%[59]. - The company has applied for 28 new patents and obtained 17 new patents during the reporting period, totaling 122 valid patents by the end of the period[55]. - The company has developed a unique AI drug discovery platform that generates molecules with superior drug-likeness, significantly reducing computational requirements[73]. - The company achieved breakthroughs in structural biology services, enhancing its capabilities in early-stage compound discovery across various disease areas[74]. Market Trends and Challenges - The company faces potential risks including a decline in drug research market demand, changes in industry policies, intensified market competition, and quality control risks[3]. - The success rate of clinical development across all therapeutic areas dropped to 6.3% in 2022, indicating increased challenges in drug development[37]. - The Chinese CDMO market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% over the next five years, double the global growth rate[38]. - Emerging biotech companies contributed to 72% of the clinical development pipeline, highlighting a shift in innovation dynamics within the pharmaceutical industry[36]. Corporate Governance - The company has a comprehensive governance structure in place, ensuring effective checks and balances among its decision-making bodies[149]. - The company maintains a complete and independent operational capability, with clear separation from its controlling shareholders in terms of assets, personnel, and business operations[150]. - The company has established an independent financial department with specialized personnel, ensuring financial operations are independent from controlling shareholders and their other enterprises[152]. - The company has a structured governance framework, including a shareholder meeting, board of directors, supervisory board, and management team, ensuring independent operational management[153]. - The company has not faced any penalties from securities regulatory agencies in the past three years for its current and former directors and supervisors[171]. Employee and Talent Management - The company has attracted over 1,000 graduates from renowned universities in recent years, enhancing its talent pool[57]. - The company has implemented a stock incentive plan, granting 981,100 restricted shares to 206 mid-to-senior level employees to enhance employee motivation and retention[94]. - The company has a total of 12 directors and supervisors, with the highest individual remuneration being RMB 234,000 for the general manager[176]. - The company has a total of 2,487 employees, with 1,508 technical personnel, representing approximately 60.5% of the total workforce[186]. - The company has established a dual career development path for employees, focusing on both professional and managerial growth[188]. Environmental and Social Responsibility - The company is committed to promoting green pharmaceutical manufacturing and exploring innovative low-carbon technologies[139]. - The company has increased investment in environmental protection facilities and improved management levels to ensure safety in production and environmental protection[142]. - The company has not experienced any major safety or environmental incidents since its establishment, despite increasing pressure from expanding business operations[142]. Financial Management and Fundraising - The company successfully issued convertible bonds, resulting in an increase in payable bonds to ¥1,045,631,907.14, which accounted for 21.51% of total liabilities[114]. - The company raised a total of RMB 1,143,301,603.77 through the issuance of convertible bonds in 2022, with actual usage amounting to RMB 1,127,545,752.36[128]. - The company has a remaining unused raised fund amount of CNY 45,496,090[126]. - The company reported a fair value change gain of CNY 3,352,426.59 as of December 31, 2022[122]. - The company has a structured remuneration decision-making process involving the compensation and assessment committee[172]. Dividend Policy - The company reported a cash dividend of RMB 1.00 per 10 shares, totaling RMB 19,966,421.70, which represents 100% of the total distributable profit[192]. - The company has established a cash dividend policy that requires a minimum of 20% of profits to be distributed as cash dividends during growth phases with significant capital expenditures[192]. - The company’s cash dividend distribution was completed by June 13, 2022, following the shareholder meeting on April 4, 2022[190].

Financial Performance - The company's revenue for Q1 2023 was CNY 383,440,937.44, representing a 14.24% increase compared to CNY 335,643,580.55 in the same period last year[6] - Net profit attributable to shareholders decreased by 18.47% to CNY 57,755,969.84 from CNY 70,839,845.23 year-on-year[6] - The basic earnings per share fell by 19.44% to CNY 0.29 from CNY 0.36 in the same period last year[6] - Net profit for Q1 2023 was ¥57,755,961.44, a decrease of 22.3% from ¥74,367,424.72 in Q1 2022[24] - The total comprehensive income attributable to the parent company was CNY 56,506,003.88, a decrease from CNY 70,600,622.80 in the previous period, representing a decline of approximately 19.99%[25] Cash Flow - The net cash flow from operating activities surged by 277.85% to CNY 75,015,353.97, up from CNY 19,853,090.75 in the previous year[6] - The net cash flow from operating activities was CNY 75,015,353.97, significantly up from CNY 19,853,090.75 in the previous period, indicating an increase of approximately 276.56%[28] - The total cash inflow from investment activities was CNY 119,249,255.06, down from CNY 771,161,653.00 in the previous period, reflecting a decrease of about 84.54%[28] - The net cash flow from financing activities was CNY 160,009,193.27, compared to CNY 152,081,619.07 in the previous period, showing an increase of approximately 5.87%[28] - The total cash and cash equivalents at the end of the period were CNY 820,190,549.66, compared to CNY 691,525,233.54 at the end of the previous period, an increase of approximately 18.61%[28] Assets and Liabilities - The company's total assets grew by 2.93% to CNY 5,004,414,338.77 from CNY 4,862,189,119.46 at the end of the previous year[6] - Current liabilities totaled ¥757,364,339.56, a slight increase from ¥739,178,415.06 in the previous year[22] - Long-term borrowings increased to ¥396,740,667.16, compared to ¥346,740,667.16 in Q1 2022, reflecting a growth of 14.4%[22] - The equity attributable to shareholders of the parent company rose to ¥2,721,037,027.73, compared to ¥2,657,635,982.95 in the previous year[22] Research and Development - Research and development expenses increased by 75.81% to CNY 48,393,224.73, compared to CNY 27,526,324.50 in the same period last year[10] - Research and development expenses rose to ¥48,393,224.73, a significant increase of 75.7% compared to ¥27,526,324.50 in the same period last year[24] Revenue Segments - The CDMO segment contributed ¥294,454,899.25, accounting for 76.79% of total revenue, with a year-on-year growth of 15.50%[18] - The company’s revenue from molecular building blocks was ¥87,016,896.24, which is 22.69% of total revenue, showing an 11.55% increase year-on-year[18] - The company’s other revenue segment saw a decline of 26.89% year-on-year, totaling ¥1,969,141.95[18] Shareholder Information - The top shareholder, Yang Minmin, holds 20.69% of the shares, with 30,980,264 shares pledged[16] - The total number of common stock shareholders at the end of the reporting period was 28,597[13] - The total number of restricted shares at the end of the period was 31,211,339, with no new restrictions added during the period[16] Operational Metrics - The company reported a gross profit margin of approximately 45.5% for Q1 2023, down from 52.2% in Q1 2022[24] - Total operating costs increased to ¥344,985,836.29, up 35.5% from ¥254,700,510.42 in the previous year[23] - The company reported a significant increase in cash received from tax refunds, which rose by 78.48% to CNY 29,222,569.06 from CNY 16,372,641.23 year-on-year[10] - The company experienced a decrease in cash flow from investment activities, with cash recovered from investments dropping by 85.46% to CNY 111,529,536.99 from CNY 767,284,122.10 in the previous year[11] - The company did not conduct any mergers or acquisitions during the reporting period, with no net profit reported from merged entities[25]

南京药石科技股份有限公司（以下简称"公司"）定于2023年5月5日（星期 五）15:00至17:00在全景网举办2022年度业绩网上说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登录全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2023-042 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 （问题征集专题页面二维码） 特此公告。 南京药石科技股份有限公司董事会 2023年4月22日 出席本次业绩说明会的人员有：公司董事长杨民民先生、财务总监兼董事会 秘书吴奕斐女士、独立董事WEIZHENG XU先生、保荐代表人唐澍女士。 为充分尊重投资者，进一步提升本次业绩说明会的交流效果及针对性，现就 公司2022年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意 ...

专注化学，创新医药 | --- | --- | --- | |---------------------------------------------|-------|------------------| | | | | | | | | | 药石科技 2020 2020 年9月2日 | | 年中期业绩交流会 | | | | | | | | | | www.pharmablock.com product.pharmablock.com | | | | | | | Confidential 保密 01 P A R T业务持续增长 cninf 空 www.cninf.com.cn Confidential 保密 财务数据 PharmaBlock 营业收入 归属于上市公司 股东的净利润 8734万元 同比增长 58.17% 同比增长 26.08% 同比增长 25.41% 同比增长 388.81% 基本每股收益 0.6元/股 同比增长 25.00% 加权平均 净资产收益率 11.05% 同比增长 0.10% 总资产 13.13亿元 同比增长 27.63% 归属于上市公司 股东的净资产 8.29亿元 同比增长 11. ...